A blog about chemistry, drug development, science, and technology
Lately, it seems that more and more drugs are coming under scrutiny for possibly increasing the risk of heart problems. The latest is Evista (raloxifene), an osteoporosis drug.
Breast cancer drug’s ties to heart ailments explored
The title itself is confusing. First, Evista has been shown in the study quoted to reduce the likely hood of developing breast cancer. The article also mentions Nolvadex (tamoxifen) which I’ve posted on before which has been shown to be less effective than Evista.
Here’s the quote from the article:
After about six years, women who had taken the drug were 44 percent more likely to have had a blood clot than were those in the placebo group and 49 percent more likely to have died from a stroke — each translating to about one more instance per 1,000 women treated each year. Overall, the two groups had heart problems at the same rate (533 events such as heart attacks and heart failure).
As I always state, all drugs, even over-the-counter drugs, have risks associated with them. The key is does the benefit outweigh the risk. This is always the case but it rarely gets thought out. Patients may not know the risks and doctors don’t often talk about the side-effects and risks.
I always recommend that patients read the full prescribing information (aka patient package insert) for any medication you are taking. While this may take some effort on some folks part, it is definitely worth it.
The first place to look for the prescribing information (if it doesn’t come with your prescription) is on the website for the medication or the company that produces it. As an example, I would try the following:
www.evista.com
This does indeed bring up the correct website for Evista.
You can also look at the Eli Lilly company website (they are the makers of Evista).
Also, the FDA website has a lot of information for approved drugs. You can find them at Drugs@FDA, and then give at least three letters for the drug and it will give you information on it although the prescribing information isn’t always included.
Technorati Tags: Evista, raloxifene, Tamoxifen
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 1.205 seconds